Walden Biosciences
Ming Proschitsky has worked in the biotechnology industry since 2011. Ming began their career as a Research Scientist at NeuroPhage Pharmaceuticals, Inc. in 2011. In 2014, they were promoted to Senior Scientist at NeuroPhage Pharmaceuticals / Proclara Biosciences. In 2018, they were promoted again to Principal Scientist at Proclara Biosciences. In 2019, they moved to Pandion Therapeutics as Principal Scientist, Therapeutic Protein Technologies. Currently, they are the Head of BioTherapeutics at Walden Biosciences.
Ming Proschitsky attended Tsinghua University from 1999 to 2003, where they received a B.S. in Biological Science. Ming then attended Boston University School of Medicine from 2004 to 2010. No additional certifications were listed.
This person is not in any offices
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.